Today: 18 July 2026
Apple Stock Gets Mixed Signals: UBS Stays Neutral as App Store Growth Cools
6 January 2026
1 min read

Apple Stock Gets Mixed Signals: UBS Stays Neutral as App Store Growth Cools

New York, Jan 6, 2026, 11:20 EST

  • UBS reiterated a Neutral rating on Apple and kept a $280 price target, citing slower App Store growth in the December quarter.
  • BofA Securities and Evercore ISI maintained bullish calls and $325 targets, pointing to steadier App Store trends.
  • Analysts flagged gaming and China as key soft spots in recent App Store data.

UBS reiterated a Neutral rating on Apple on Tuesday and kept a $280 price target, saying App Store growth slowed in the December 2025 quarter. The bank estimated growth at about 7%, down from 12% and 10% in the June and September 2025 quarters, and about 5% on a foreign-exchange-neutral basis — stripping out currency swings. UBS said the March 2026 quarter still looks like a hurdle even with easier comparisons of roughly 200 basis points, or two percentage points.

The App Store is a key driver of Apple’s services business, which investors watch closely for recurring revenue and higher margins than hardware. Third-party app spending and download data has become a common read-through for the December quarter, Apple’s fiscal first quarter, when holiday demand can swing results.

The focus is sharpened by the fact that Apple does not break out App Store revenue in its financial statements. That leaves investors leaning on analyst models and external trackers for clues on whether services growth is holding up as the iPhone market matures.

BofA Securities analyst Wamsi Mohan reiterated a Buy rating and a $325 target, estimating App Store revenue of about $8.6 billion for Apple’s fiscal first quarter, up 6.8% from a year earlier, based on third-party tracking. Evercore ISI’s Amit Daryanani also reiterated an Outperform rating and kept a $325 target, saying App Store revenue growth has run around 6% in recent months even as gaming remains the main drag, particularly in China and Japan. Daryanani said categories such as social networking, music, and photo and video apps showed gains, and he expects Apple Pay, iCloud and licensing to help support overall services revenue.

Evercore separately said App Store revenue appeared to have stabilized in December despite persistent weakness in gaming, according to a report by Seeking Alpha. Daryanani pegged December App Store revenue growth at about 6% year-on-year.

Apple’s App Store is one of the biggest mobile software storefronts, competing with Alphabet’s Google Play for developer fees and consumer spending. Investors have treated App Store trends as a bellwether for broader digital spending, including subscriptions and in-app purchases.

The swing factor is gaming and China. If gaming remains weak into early 2026 — or if lower fees and other pricing pressure intensify in key markets — services expectations may soften and valuation headroom could narrow.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • SELLAS Life Sciences Jumps on Phase 3 Trial Hopes; High Valuation Poses Questions
    July 18, 2026, 2:52 AM EDT. SELLAS Life Sciences Group (SLS) gained 70% over the last month and is up 203% year-to-date, fueled by rising expectations about Phase 3 results for galinpepimut-S in acute myeloid leukemia. Shares recently traded at $13.19 with a price-to-book ratio of 24.1x, well above both the peer average of 9.1x and the biotechnology sector average of 2.6x, putting the stock at a rich valuation. The premium reflects investor confidence even as SELLAS remains unprofitable and posts negative return on equity. Final trial data offers a key upcoming catalyst, but significant risks persist due to the binary outcome of clinical studies and the absence of current revenue. Investors are urged to consider these factors in line with their individual risk profiles.
Blackbaud stock slides nearly 6% to start 2026 as investors eye jobs data and mid-Feb earnings window
Previous Story

Blackbaud stock slides nearly 6% to start 2026 as investors eye jobs data and mid-Feb earnings window

Oracle stock slips after UBS says junk-rating fears look overdone as AI debt grows
Next Story

Oracle stock slips after UBS says junk-rating fears look overdone as AI debt grows

Go toTop